Stryker Corporation (NYSE:SYK – Get Free Report) Director Ronda Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Stryker Price Performance
Stryker stock opened at $307.22 on Friday. The firm has a market cap of $117.78 billion, a PE ratio of 35.56, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company’s 50 day moving average is $322.61 and its two-hundred day moving average is $348.45.
Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.
Stryker Announces Dividend
Institutional Investors Weigh In On Stryker
Several hedge funds and other institutional investors have recently bought and sold shares of SYK. Norges Bank acquired a new stake in Stryker during the 4th quarter worth $1,822,272,000. Auto Owners Insurance Co raised its stake in Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares in the last quarter. Wellington Management Group LLP raised its stake in Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC raised its stake in Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Stryker by 241.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,555,638 shares of the medical technology company’s stock worth $511,167,000 after acquiring an additional 1,100,673 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
SYK has been the topic of a number of analyst reports. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. BTIG Research reduced their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Leerink Partners initiated coverage on shares of Stryker in a report on Monday, April 13th. They issued an “outperform” rating and a $410.00 price objective on the stock. Citigroup reduced their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Finally, Barclays reduced their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $395.48.
View Our Latest Research Report on Stryker
Stryker Company Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Stories
- Five stocks we like better than Stryker
- China Deal Ignites Boeing’s Financial Afterburners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
